Unmet Needs in the Treatment of RA in the Era of Jak-i: IDRA (Italian Delphi Rheumatoid Arthritis) Consensus
Table 2
Answers to the Delphi questionnaire. (Items 3 and 4). The table shows the Delphi questionnaire and the answers relating to the individual items. The answers given by the Delphi participants are expressed in numerical terms. The percentages indicate the sum of the answers related to nonconsensus (1, 2) and consensus (3, 4, and 5).
Significant fatigue improvement
3. Fatigue continues to have a significant negative impact on over half of patients with RA, and it is a factor that impacts on patient's quality of life. I think that:
1
2
3
4
5
3.1 Only in a certain percentage of patients fatigue is related to the progression of the disease
1
8
15
19
5
19
81
3.2 Fatigue is not always a valid indicator to evaluate the effectiveness of a therapy
1
5
13
17
12
13
87
3.3 The FACIT-fatigue (Functional Assessment of Chronic Illness – fatigue) in Italian is a valid index to monitor the fatigue
1
2
24
17
4
6
94
3.4 It is correct to include the extent of fatigue in clinical trial
1
1
17
20
9
4
96
3.5 Fatigue can correlate significantly with mood
1
0
8
16
23
2
98
Satisfactory levels of physical functioning
4. Physical functioning levels depend on disease activity, structural damage and fatigue. Current therapies do not often provide satisfactory levels of physical functioning Therefore to improve physical functioning I consider important:
1
2
3
4
5
4.1 Intervening at an early stage with second-level drugs (bDMARDS o tsDMARDs)
2
0
6
20
20
4
96
4.2 Implementing a T2T strategy with closer monitoring
1
0
4
19
24
2
98
4.3 Improving adherence to therapy in order to have optimal control of the disease
1
0
4
19
24
2
98
4.4 Starting a joint education program immediately after the onset of the disease
1
1
17
16
13
4
96
4.5 Always administering a low dose of cortisone in association with DMARDs
4
13
23
6
2
35
65
4.6 Administering a low dose of cortisone in association with DMARD for a limited period
